ICONHome   ICONContact us   ICONAdd Favorites
Biochemtek
Search Product
Live Chat E-mail
Pharmacology
ICON Inhibitors
ICON Receptors
ICON Hedgehog Signaling Pathway
ICON Stem Cells & Wnt
ICON Signal Transduction
 　 More +
Research Area
ICON Cancer
ICON Antivirus
ICON Cardiovascular System
ICON Endocrinology
ICON Neuroscience
 　 More +
Product Type
ICON Natural Products
ICON Peptides
ICON Prostaglandins
ICON Vitamin D series compounds
ICON Toxins
 　 More +
Browse Alphabetically by Name
ALL A B C D E F
G H I J K L M
N O P Q R S T
U V W X Y Z Others
 
ICONC13823 ABT-869(Linifanib) (796967-16-3)
 
 
Catalog No.: C13823
CAS No.: 796967-16-3
Synonym: Linifanib,AL-39324,RG3635
Chemical Name:

N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea
Molecular Formula: C21H18FN5O
Molecular Weight: 375.41
 
Technical Data:
Appearance:
Solubility: Soluble in DMSO
Purity: >99%
Storage: at -20℃ 2 years
Original QC Data:
Shipping Conditions: Ambient Temp.
 
Price and Availability of ABT-869(Linifanib):

Size

Price

Stock

10mg 

USD

In stock 

50mg 

USD

In stock 

100mg 

USD

In stock 

Contact us for competitive discounts on bulk quantities
 
Biological Activity:
ABT-869 is multi-targeted in that it is a potent inhibitor of all members of the VEGF and PDGF receptor families (e.g., KDR IC50 value of 4 nM), but has much less activity (IC50 values >1 µM) against unrelated receptor tyrosine kinases, soluble tyrosine kinases or serine/threonine kinases. The kinase inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 values of 2, 4 and 7 nM for PDGFRß, KDR and CSF-1R, respectively) and VEGF-stimulated proliferation (0.2 nM IC50 for human endothelial cells).
 
References:

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Shankar DB,et al Blood. 2007 Apr 15;109(8):3400-8.

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Albert DH, Mol Cancer Ther. 2006 Apr;5(4):995-1006.

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Zhou J,Leuk Res. 2008 Jul;32(7):1091-100. Epub 2007 Dec 26
 
View Related Products by Target:
Nilotinib(AMN 107)
NVP-TAE684-TAE 684
Motesanib(AMG706)
Imatinib mesylate(STI-571)
BIBW 2992(Afatinib)
Dovitinib lactate(TKI258)
Pelitinib(EKB-569)
PF 2341066(Crizotinib)
BIBF1120(Vargatef)
CHIR-258(Dovitinib,TKI258)
Brivanib alaninate(BMS-582664)
Lapatinib Ditosylate (GW-572016)
 
 

Keywords: Buy ABT-869(Linifanib) | ABT-869(Linifanib) Supplier | Purchase ABT-869(Linifanib) | ABT-869(Linifanib) Cost | ABT-869(Linifanib)  Manufacturer | Order ABT-869(Linifanib) | ABT-869(Linifanib) Distributor | ABT-869(Linifanib) Structure, Chembest

Buy 796967-16-3| 796967-16-3 Supplier | Purchase 796967-16-3 | 796967-16-3 Cost | 796967-16-3 Manufacturer | Order 796967-16-3 | 796967-16-3 Distributor | 796967-16-3 Structure, Chembest  
Products are for research use only. Not for human use. We do not sell to patients.
Copyright © 2010-2024 Chembest Research Laboratories. All Rights Reserved
E-mail:sales@biochembest.com